Mebendazole, a prescription drug used in humans to treat parasites, and fenbendazole, a treatment for parasites in animals, show promising but so far very preliminary evidence of anticancer effects.
We review the scientific literature and rate the strength of evidence for supplements and therapies for cancer outcomes. Explore our database ›
Mebendazole or fenbendazole at a glance
Mebendazole and fenbendazole are two familiar drugs for treating parasites. While several similar drugs have been studied in preclinical trialstesting a drug, a procedure, or another medical treatment in isolated cells or in animals; preclinical evidence is considered only an initial indication of possible effects in people (cells and animal studies), only mebendazole has been studied for anticancer effects in humans. In this review, we focus primarily on mebendazole, a prescription drug used with humans, and fenbendazole, a treatment for animals.
Mebendazole shows promising anticancer effects in preclinical (cell and animal) studies and some initial trials in humans. Fenbendazole also shows promising preclinical evidence of anticancer effects. However, some evidence also shows accelerated disease progression among people with advanced gastrointestinal cancer.
CancerChoices ratings for mebendazole or fenbendazole
We rate mebendazole or fenbendazole on seven attributes, with 0 the lowest rating and 5 the highest. We rate the strength of the evidence supporting the use of mebendazole or fenbendazole for a medical benefit, such as improving treatment outcomes or managing side effects.
See how we evaluate and rate complementary therapies ›